Think you might have a banana allergy
The main conclusion is well supported because the primary endpoint was clearly negative in both trials. How does this work fit with the existing evidence
It's designed to work in harmony with the body's own signaling mechanisms to support repair, balance, and resilienceparticularly in tissues like the gut, joints, and muscles
What compensation can I expect
According to the World Health Organization, more than 1.9 billion adults worldwide are overweight, and 39% of adults globally were classified as overweight in 2016
Patrick Kee, MD, PhD, a cardiologist at Vital Heart & Vein, who was not involved in the study, noted the following about the studys results: The investigators demonstrated that the therapeutic efficacy of semaglutide on the primary cardiovascular composite endpoint indeed emerged early and persisted over the initial three months (hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.41-0.95) and the subsequent six months (HR 0.60, 95% CI 0.44-0.81). While the underlying mechanisms of semaglutides early clinical benefits remain under investigation, these findings suggest an encouraging intervention capable of altering the trajectory of [patients with obesity] with established cardiovascular disease but without a diagnosis of diabetes, he told Medical News Today
.webp)
